Lupin has informed about Press Release as regards receipt of US FDA approval by the Company for Phenylephrine and Ketorolac Intraocular Solution, 1%/0.3%, which is the generic version of Omidria Intraocular Solution, 1%/0.3%, of Omeros Corporation. This is considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015.
The above information is a part of company’s filings submitted to BSE.